T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR

Regulatory T (Treg) cells safeguard against autoimmunity and immune pathology. Because determinants of the Treg cell fate are not completely understood, we have delineated signaling events that control the de novo expression of Foxp3 in naive peripheral CD4 T cells and in thymocytes. We report that...

Full description

Saved in:
Bibliographic Details
Published inProceedings of the National Academy of Sciences - PNAS Vol. 105; no. 22; pp. 7797 - 7802
Main Authors Sauer, Stephan, Bruno, Ludovica, Hertweck, Arnulf, Finlay, David, Leleu, Marion, Spivakov, Mikhail, Knight, Zachary A, Cobb, Bradley S, Cantrell, Doreen, O'Connor, Eric, Shokat, Kevan M, Fisher, Amanda G, Merkenschlager, Matthias
Format Journal Article
LanguageEnglish
Published United States National Academy of Sciences 03.06.2008
National Acad Sciences
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Regulatory T (Treg) cells safeguard against autoimmunity and immune pathology. Because determinants of the Treg cell fate are not completely understood, we have delineated signaling events that control the de novo expression of Foxp3 in naive peripheral CD4 T cells and in thymocytes. We report that premature termination of TCR signaling and inibition of phosphatidyl inositol 3-kinase (PI3K) p110α, p110δ, protein kinase B (Akt), or mammalian target of rapamycin (mTOR) conferred Foxp3 expression and Treg-like gene expression profiles. Conversely, continued TCR signaling and constitutive PI3K/Akt/mTOR activity antagonised Foxp3 induction. At the chromatin level, di- and trimethylation of lysine 4 of histone H3 (H3K4me2 and -3) near the Foxp3 transcription start site (TSS) and within the 5' untranslated region (UTR) preceded active Foxp3 expression and, like Foxp3 inducibility, was lost upon continued TCR stimulation. These data demonstrate that the PI3K/Akt/mTOR signaling network regulates Foxp3 expression.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Edited by Christophe Benoist, Joslin Diabetes Center, Boston, MA, and approved April 7, 2008
Author contributions: M.M. designed research; S.S., L.B., A.H., D.F., B.S.C., E.O., and M.M. performed research; Z.A.K., D.C., and K.M.S. contributed new reagents/analytic tools; S.S., L.B., A.H., M.L., M.S., Z.A.K., A.G.F., and M.M. analyzed data; and M.M. wrote the paper.
ISSN:0027-8424
1091-6490
DOI:10.1073/pnas.0800928105